Pfizer (PFE) Invested Capital (2009 - 2026)

Pfizer (PFE) has 18 years of Invested Capital data on file, last reported at $91.0 billion in Q1 2026.

• Invested Capital for Q1 2026 came in at $91.0 billion, down 0.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $91.0 billion (down 0.53% YoY), and the FY2025 annual result was $87.4 billion, down 2.15% from the prior year.
• Invested Capital improved to $91.0 billion in Q1 2026 per PFE's latest filing, from $87.4 billion in the prior quarter.
• Over five years, Invested Capital peaked at $102.0 billion in Q2 2023 and troughed at $83.5 billion in Q2 2022.
• A 5-year average of $92.4 billion and a median of $91.4 billion in 2025 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2024: Invested Capital soared 153.13% in 2022, then slipped 11.32% in 2024.
• A 5-year view of Invested Capital shows it stood at $96.7 billion in 2022, then fell by 6.82% to $90.1 billion in 2023, then decreased by 0.93% to $89.3 billion in 2024, then decreased by 2.15% to $87.4 billion in 2025, then gained by 4.13% to $91.0 billion in 2026.
• Business Quant data shows PFE's Invested Capital at $91.0 billion in Q1 2026, $87.4 billion in Q4 2025, and $94.0 billion in Q3 2025.